NR3C1 and Hypoglycemia: Administration of the GR antagonist RU486 prior to hypoglycemia on study days 1–3 caused significant augmentation of GAD profiles during hypoglycemia on day 4 (Figure 6B) [RU/IIII (dark gray bar) versus V/IIII (diagonal-striped light gray bar); t(5) = 3.13, p = 0.02].